ALNY Financial Facts
Total other income (expense): 2.32MUnrealized (loss) gain on marketable securities: -18.33M
See Full Income Statement
Marketable securities: 571.99M
Cash and cash equivalents: 271.08M
See Full Balance Sheet
Alnylam Pharmaceuticals, Inc. (ALNY) Earnings
|
Expand Research on ALNY
| Next EPS Date | 5/2/24 | EPS Growth Rate | -7.5% |
|---|---|---|---|
| Average EPS % Beat Rate | +75.3% | Revenue Growth Rate | +33.0% |
| Average % Move 1-Wk after EPS | +1.9% | Normal Earnings Time | Before Open |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2/15/24 | Q423 | -$0.77 | -$1.26 | +$0.49 | $439.72M | $436.08M | = |  | | Details | |
5/2/24  |
Q124 | N/A | -$1.14 | N/A | N/A | $424.52M | = | N/A | N/A | ||
| 11/2/23 | Q323 | $1.74 | -$1.32 | +$3.06 | $750.5M | $397.99M | N/A | | | Details | |
| 8/3/23 | Q223 | -$1.62 | -$1.52 | -$0.10 | $318.75M | $332.83M | N/A | | | Details | |
| 5/4/23 | Q123 | -$1.06 | -$1.68 | +$0.62 | $319.29M | $312.27M | N/A | | | Details | |
| 2/23/23 | Q422 | -$1.39 | -$1.85 | +$0.46 | $335.04M | $312.2M | N/A | | | Details | |
| 10/27/22 | Q322 | -$1.58 | -$1.73 | +$0.15 | $264.3M | $293.08M | = | | | Details | |
| 7/28/22 | Q222 | -$2.03 | -$1.61 | -$0.42 | $224.82M | $255.87M | = | | | Details |
